Forecast to Publish a Funding Opportunity Announcement for Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)

The Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) funding opportunity is issued by the National Institutes of Health through the National Cancer Institute. The program reflects NCI’s long-standing investment in cancer epidemiology cohort studies, which have contributed significantly to understanding environmental, behavioral, and genomic factors influencing cancer risk and survivorship. The initiative seeks to expand, modernize, and sustain cohort-based research infrastructure to address emerging scientific questions and evolving population dynamics. The primary purpose of this funding opportunity is to support hypothesis-driven research within cancer epidemiology cohorts that address knowledge gaps in cancer etiology and survivorship. The program encourages both the use of existing cohort data and the development or expansion of new cohorts. Proposed research must demonstrate scientific rigor and relevance, including the ability to generate insights that can reduce cancer incidence, morbidity, and mortality, and improve quality of life among survivors. The initiative also emphasizes longitudinal study designs that systematically collect exposure, biospecimen, and outcome data over time. Funding under this opportunity is provided through a cooperative agreement mechanism (U01), indicating substantial involvement by NIH program staff throughout the project period. Budgets are not capped but must reflect the actual needs of the proposed research, and the maximum project period is five years. Allowable activities include hypothesis-driven analyses, infrastructure support tied directly to scientific aims, cohort expansion, and development of new cohorts with robust data collection systems. The program places strong emphasis on data sharing, biospecimen management, and long-term sustainability of cohort resources beyond the funding period. Eligibility for this opportunity is broad and inclusive. Applicants may include public and private institutions of higher education, nonprofit organizations, for-profit entities, small businesses, state and local governments, tribal governments, and foreign organizations. Individual investigators must demonstrate the necessary expertise and institutional support to carry out the proposed research. There is no cost-sharing requirement, lowering financial barriers to participation. However, applicants must comply with extensive NIH registration requirements, including SAM, Grants.gov, and eRA Commons registrations prior to submission. The application process follows standard NIH submission procedures. Applications must be submitted electronically through systems such as NIH ASSIST, Grants.gov Workspace, or institutional system-to-system solutions. Required components include a detailed research plan, specific aims, preliminary data, cohort overview (if applicable), data management and sharing plan, and letters of support. Applications are evaluated through NIH’s peer review system based on significance, innovation, rigor, feasibility, investigator expertise, and institutional environment. Additional considerations include data sharing compliance, community engagement, and cohort sustainability planning. The funding opportunity operates on recurring standard NIH due dates. The earliest submission date is September 5, 2026, with the first application due date on October 5, 2026, followed by additional cycles in February and June annually through June 2029. Applications are due by 5:00 PM local time of the applicant organization. Review cycles occur several months after submission, with earliest project start dates approximately nine months after the application deadline. The opportunity expires on July 6, 2029, indicating a multi-year recurring funding cycle with multiple submission opportunities. Overall, this program is designed to strengthen the national cancer research infrastructure by supporting high-quality epidemiological cohort studies. By integrating innovative data collection methods, community engagement, and rigorous scientific inquiry, the initiative aims to generate actionable knowledge that can inform cancer prevention strategies, improve survivorship outcomes, and ultimately reduce the burden of cancer across populations.

Align proposal with NIH review criteria emphasizing significance, rigor, feasibility, and innovation; demonstrate strong cohort design and sustainability; ensure compliance with data sharing and community engagement requirements